Symbols

MDT

Medtronic·NYSE

--(--)

MDT fundamentals

MDT Q3 2026 Earnings

Medtronic (MDT) released its earnings on Feb 17, 2026: revenue was 9.02B (YoY +8.74%), beat estimates; EPS was 1.36 (YoY -2.16%), beat estimates.

Revenue / YoY

9.02B

+8.74%

EPS / YoY

1.36

-2.16%

Report date

Feb 17, 2026

MDT Earnings Call Summary for Q3,2026

Revenue Beat: 6% organic growth ($9B total), CAS up 80% YoY, EPS $1.36 (+$0.03).
PFA Dominance: Sphere-9 catheter 200% growth, Sphere-360 U.S. trial begins.
New Growth Engines: Symplicity RDN website visits +50x, Altaviva training 500+ physicians.
Robotics Expansion: Hugo U.S. launch with first cases, Stealth AXiS FDA-cleared for spine.
FY27 Outlook: High single-digit EPS growth, CAS/ Diabetes mix improving, $0.04-$0.05 M&A dilution.

Earnings

EPS

Revenue

Revenue & Expenses

MDT has released its 2026 Q3 earnings report, with revenue of 9.02B, reflecting a YoY change of 8.74%, and net profit of 1.15B, showing a YoY change of -11.74%. The Sankey diagram below clearly presents MDT's revenue sources and cost distribution.

Key Indicators

Medtronic (MDT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Medtronic (MDT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Medtronic (MDT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Medtronic (MDT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown